|
1
|
Li F and Ling X: Survivin study: an update
of ‘what is the next wave’? J Cell Physiol. 208:476–486. 2006.
|
|
2
|
Li F: Survivin study: what is the next
wave? J Cell Physiol. 197:8–29. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jha K, Shukla M and Pandey M: Survivin
expression and targeting in breast cancer. Surg Oncol. 21:125–131.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Altieri DC: New wirings in the survivin
networks. Oncogene. 27:6276–6284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Altieri DC: Survivin, cancer networks and
pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Guha M and Altieri DC: Survivin as a
global target of intrinsic tumor suppression networks. Cell Cycle.
8:2708–2710. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Waligórska-Stachura J, Jankowska A, Waśko
R, et al: Survivin - prognostic tumor biomarker in human neoplasms
- review. Ginekol Pol. 83:537–540. 2012.PubMed/NCBI
|
|
8
|
Sarti M, Pinton S, Limoni C, et al:
Differential expression of testin and survivin in breast cancer
subtypes. Oncol Rep. 30:824–832. 2013.PubMed/NCBI
|
|
9
|
Dedić Plavetić N, Jakić-Razumović J, Kulić
A and Vrbanec D: Prognostic value of proliferation markers
expression in breast cancer. Med Oncol. 30:5232013.
|
|
10
|
Song J, Su H, Zhou YY and Guo LL:
Prognostic value of survivin expression in breast cancer patients:
a meta-analysis. Tumour Biol. 34:2053–2062. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu C, Yamamoto-Ibusuki M, Yamamoto Y, et
al: High survivin mRNA expression is a predictor of poor prognosis
in breast cancer: a comparative study at the mRNA and protein
level. Breast Cancer. Sep 12–2012.(Epub ahead of print).
|
|
12
|
Li X, Dang X and Sun X: Expression of
survivin and VEGF-C in breast cancer tissue and its relation to
lymphatic metastasis. Eur J Gynaecol Oncol. 33:178–182.
2012.PubMed/NCBI
|
|
13
|
Adamkov M, Kajo K, Vybohova D, Krajcovic
J, Stuller F and Rajcani J: Correlations of survivin expression
with clinicomorphological parameters and hormonal receptor status
in breast ductal carcinoma. Neoplasma. 59:30–37. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kapoor S: Beyond pancreatic carcinoma: The
close relationship between survivin levels and prognosis in
systemic malignancies. World J Clin Oncol. 3:80–81. 2012.
View Article : Google Scholar
|
|
15
|
Johnson ME and Howerth EW: Survivin: a
bifunctional inhibitor of apoptosis protein. Vet Pathol.
41:599–607. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gazouli M, Tzanakis N, Rallis G, et al:
Survivin −31G/C promoter polymorphism and sporadic colorectal
cancer. Int J Colorectal Dis. 24:145–150. 2009.
|
|
17
|
Li XB, Li SN, Yang ZH, Cao L, Duan FL and
Sun XW: Polymorphisms of survivin and its protein expression are
associated with colorectal cancer susceptibility in Chinese
population. DNA Cell Biol. 32:236–242. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu Y, Fang F, Ludewig G, Jones G and Jones
D: A mutation found in the promoter region of the human survivin
gene is correlated to overexpression of survivin in cancer cells.
DNA Cell Biol. 23:419–429. 2004. View Article : Google Scholar
|
|
19
|
Boidot R, Vegran F, Jacob D, et al: The
expression of BIRC5 is correlated with loss of specific chromosomal
regions in breast carcinomas. Genes Chromosomes Cancer. 47:299–308.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li F and Altieri DC: Transcriptional
analysis of human survivin gene expression. Biochem J. 344:305–311.
1999. View Article : Google Scholar
|
|
21
|
Xu R, Zhang P, Huang J, Ge S, Lu J and
Qian G: Sp1 and Sp3 regulate basal transcription of the survivin
gene. Biochem Biophys Res Commun. 356:286–292. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mityaev MV, Kopantzev EP, Buzdin AA,
Vinogradova TV and Sverdlov ED: Functional significance of a
putative Sp1 transcription factor binding site in the survivin gene
promoter. Biochemistry (Mosc). 73:1183–1191. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang G, Zhu H, Wang Y, et al:
Krüppel-like factor 4 represses transcription of the survivin gene
in esophageal cancer cell lines. Biol Chem. 390:463–469. 2009.
|
|
24
|
Li Y, Xie M, Yang J, et al: The expression
of antiapoptotic protein survivin is transcriptionally upregulated
by DEC1 primarily through multiple Sp1 binding sites in the
proximal promoter. Oncogene. 25:3296–3306. 2006. View Article : Google Scholar
|
|
25
|
Sørlie T, Perou CM, Tibshirani R, et al:
Gene expression patterns of breast carcinomas distinguish tumor
subclasses with clinical implications. Proc Natl Acad Sci USA.
98:10869–10874. 2001.PubMed/NCBI
|
|
26
|
Chin K, DeVries S, Fridlyand J, et al:
Genomic and transcriptional aberrations linked to breast cancer
pathophysiologies. Cancer Cell. 10:529–541. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
King CR, Kraus MH and Aaronson SA:
Amplification of a novel v-erbB-related gene in a human mammary
carcinoma. Science. 229:974–976. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Banerji S, Cibulskis K, Rangel-Escareno C,
et al: Sequence analysis of mutations and translocations across
breast cancer subtypes. Nature. 486:405–409. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sjöblom T, Jones S, Wood LD, et al: The
consensus coding sequences of human breast and colorectal cancers.
Science. 314:268–274. 2006.
|
|
30
|
Wood LD, Parsons DW, Jones S, et al: The
genomic landscapes of human breast and colorectal cancers. Science.
318:1108–1113. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kan Z, Jaiswal BS, Stinson J, et al:
Diverse somatic mutation patterns and pathway alterations in human
cancers. Nature. 466:869–873. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Usary J, Llaca V, Karaca G, et al:
Mutation of GATA3 in human breast tumors. Oncogene. 23:7669–7678.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ly M, Valent A, Diallo G, et al: Gene copy
number variations in breast cancer of Sub-Saharan African women.
Breast. 22:295–300. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Orsetti B, Courjal F, Cuny M, Rodriguez C
and Theillet C: 17q21–q25 aberrations in breast cancer: combined
allelotyping and CGH analysis reveals 5 regions of allelic
imbalance among which two correspond to DNA amplification.
Oncogene. 18:6262–6270. 1999.
|
|
35
|
Kalikin LM, Frank TS, Svoboda-Newman SM,
Wetzel JC, Cooney KA and Petty EM: A region of interstitial 17q25
allelic loss in ovarian tumors coincides with a defined region of
loss in breast tumors. Oncogene. 14:1991–1994. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cheng ZJ, Hu LH and Huang SJ: Correlation
of −31G/C polymorphisms of survivin promoter to tumorigenesis of
gastric carcinoma. Ai Zheng. 27:258–263. 2008.(In Chinese).
|
|
37
|
Jang JS, Kim KM, Kang KH, et al:
Polymorphisms in the survivin gene and the risk of lung cancer.
Lung Cancer. 60:31–39. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang YH, Chiou HY, Lin CT, et al:
Association between survivin gene promoter −31 C/G polymorphism and
urothelial carcinoma risk in Taiwanese population. Urology.
73:670–674. 2009.
|
|
39
|
Yang X, Xiong G, Chen X, et al:
Polymorphisms of survivin promoter are associated with risk of
esophageal squamous cell carcinoma. J Cancer Res Clin Oncol.
135:1341–1349. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Borbély AA, Murvai M, Szarka K, et al:
Survivin promoter polymorphism and cervical carcinogenesis. J Clin
Pathol. 60:303–306. 2007.
|
|
41
|
Wierstra I: Sp1: emerging roles - beyond
constitutive activation of TATA-less housekeeping genes. Biochem
Biophys Res Commun. 372:1–13. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Grant SF, Reid DM, Blake G, Herd R,
Fogelman I and Ralston SH: Reduced bone density and osteoporosis
associated with a polymorphic Sp1 binding site in the collagen type
I alpha 1 gene. Nat Genet. 14:203–205. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu W, Innocenti F, Wu MH, et al: A
functional common polymorphism in a Sp1 recognition site of the
epidermal growth factor receptor gene promoter. Cancer Res.
65:46–53. 2005.PubMed/NCBI
|
|
44
|
Miao X, Yu C, Tan W, et al: A functional
polymorphism in the matrix metalloproteinase-2 gene promoter
(−1306C/T) is associated with risk of development but not
metastasis of gastric cardia adenocarcinoma. Cancer Res.
63:3987–3990. 2003.
|
|
45
|
Yu C, Pan K, Xing D, et al: Correlation
between a single nucleotide polymorphism in the matrix
metalloproteinase-2 promoter and risk of lung cancer. Cancer Res.
62:6430–6433. 2002.PubMed/NCBI
|
|
46
|
Cheng Q, Ling X, Haller A, et al:
Suppression of survivin promoter activity by YM155 involves
disruption of Sp1-DNA interaction in the survivin core promoter.
Int J Biochem Mol Biol. 3:179–197. 2012.PubMed/NCBI
|
|
47
|
Estève PO, Chin HG and Pradhan S:
Molecular mechanisms of transactivation and doxorubicin-mediated
repression of survivin gene in cancer cells. J Biol Chem.
282:2615–2625. 2007.PubMed/NCBI
|
